Evidence map›Paper›PMID 33179452›Full record

ArticleFEBS open bio2021

Delivery of a mitochondria-targeted antioxidant from biocompatible, polymeric nanofibrous scaffolds.

Yasaman Hamedani, Rayane Brinck Teixeira, Catherine Karbasiafshar, Peter Wipf, Sankha Bhowmick, M Ruhul Abid

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yasaman HamedaniDepartment of Mechanical Engineering, University of Massachusetts Dartmouth, North Dartmouth, MA, USA.ORCID 0000-0001-6502-4415
Rayane Brinck TeixeiraDivision of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA.ORCID 0000-0001-9749-6580
Catherine KarbasiafsharDivision of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA.ORCID 0000-0003-1232-7310
Peter WipfDepartment of Chemistry, University of Pittsburgh, PA, USA.
Sankha BhowmickDepartment of Mechanical Engineering, University of Massachusetts Dartmouth, North Dartmouth, MA, USA.
M Ruhul AbidDivision of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA.ORCID 0000-0003-2981-2638
Brown University · USUniversity of Massachusetts Dartmouth · USUniversity of Pittsburgh · US

Funding

Sub-cellular Targeting of Endothelial ROS in Myocardial IschemiaR01HL133624 · NHLBI · RHODE ISLAND HOSPITAL · PI ABID, RUHUL · 2017 to 2020
$1.6M
NHLBI NIH HHS R01 HL133624
6 · The paper itself

Abstract

Cardiovascular disease has been associated with increased levels of reactive oxygen species (ROS). Recently, we have shown that a critical balance between cytosolic ROS and mitochondrial ROS is crucial in cardiovascular health and that modulation of mitochondrial ROS helps prevent detrimental effects of cytosolic ROS on endothelial cells (EC) in transgenic animals. Here, we report the development of a controlled delivery system for a mitochondria-targeted antioxidant, JP4-039, from an electrospun scaffold made of FDA-approved biocompatible polymeric nanofibers. We demonstrate that the active antioxidant moiety was preserved in released JP4-039 for over 72 h using electron paramagnetic resonance. We also show that both the initial burst release of the drug within the first 20 min and the ensuing slow and sustained release that occurred over the next 24 h improved tube formation in human coronary artery ECs (HCAEC) in vitro. Taken together, these findings suggest that electrospinning methods can be used to upload mitochondrial antioxidant (JP4-039) onto a biocompatible nanofibrous PLGA scaffold, and the uploaded drug (JP4-039) retains nitroxide antioxidant properties upon release from the scaffold, which in turn can reduce mitochondrial ROS and improve EC function in vitro.

Indexed as

AntioxidantsCardiovascular DiseasesCell LineCoronary VesselsDrug CarriersDrug LiberationEndothelial CellsHumansMitochondriaNanofibersNitrogen OxidesReactive Oxygen SpeciesAntioxidantsDrug CarriersJP4-039Nitrogen OxidesReactive Oxygen Speciesbiopolymerdrug deliveryelectrospinningendothelial cellsmitochondrial antioxidantsnanofibrous scaffold

Identifiers

PMID33179452
PMCPMC7780095
OpenAlexW3098536109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.